Galapagos NV (NASDAQ:GLPG) Q1 2023 Earnings Conference Call May 5, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Head, IR Paulus Stoffels - CEO, Chairman, Interim Head, R&D Bart Filius - President, COO & CFO Michele Manto - Chief Commercial Officer Conference Call Participants Michael Ulz - Morgan Stanley Peter Verdult - Citigroup Dane Leone - Raymond James & Associates Jason Gerberry - Bank of America Merrill Lynch Brian Balchin - Jefferies Operator Good day, and thank you for standing by. Welcom ...

EXHIBIT 99.1 Galapagos and NovAliX enter into an integrated drug discovery collaboration Mechelen, Belgium and Strasbourg, France; 30 March 2023, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and NovAliX today announced a strategic collaboration in which Galapagos' research and discovery capabilities and exclusively related employees based in Romainville, France, will be transferred to NovAliX, a drug discovery-focused Contract Research Organization. The agreement follows Galapagos' renewed focus on its ...

Product Dependence - The company reported a significant reliance on the success of filgotinib, which is approved for rheumatoid arthritis and ulcerative colitis in the EU, Great Britain, and Japan, marketed under the brand name Jyseleca[23]. - The company is heavily dependent on its global R&D collaboration with Gilead for the commercialization and development of filgotinib, with no assurance of expected benefits[20]. Financial Challenges - The company has no historical profit from product sales, making it challenging to assess future prospects and financial results[21]. - The company is prioritizing the development of certain product candidates due to limited resources and access to capital[26]. - The company may be subject to ongoing regulatory obligations and reviews, resulting in significant additional expenses if product candidates are approved[29]. Market and Competition - The company faces significant competition in drug discovery and development, which could reduce or eliminate commercial opportunities[31]. - The regulatory approval processes for product candidates are lengthy and unpredictable, which may affect commercial viability[27]. Investment and Infrastructure - The company is investing in building its marketing and sales capabilities to establish a European commercial infrastructure[22]. Market Risks - The market price of the company's American Depositary Shares (ADSs) could experience wide fluctuations[33]. - The company may face increased risks of securities class action litigation[34].

EXHIBIT 99.1 Galapagos increases share capital through subscription right exercises Mechelen, Belgium; 20 March 2023, 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises. Galapagos issued 61,560 new ordinary shares on 20 March 2023, for a total capital increase (including issuance premium) of EUR 1,769,850.00. In accordance with Belgian transparency legislation, Galapagos also wishes to note that its total sha ...

Galapagos NV (NASDAQ:GLPG) Q4 2022 Earnings Conference Call February 24, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Senior Director of Investor Relations Paul Stoffels - Chief Executive Officer Bart Filius - Chief Operating Officer & President Daniele D’Ambrosio - Head of Immunology Michele Manto - Chief Commercial Officer Conference Call Participants Phil Nadeau - Cowen Peter Verdult - Citi Brian Abrahams - RBC Capital Markets Rosie Turner - Jefferies Dane Leone - Raymond James Suzanne van Voo ...

Galapagos NV (NASDAQ:GLPG) Q2 2022 Earnings Conference Call August 5, 2022 8:00 AM ET Company Participants Sofie Van Gijsel - Senior Director of Investor Relations Paul Stoffels - Chief Executive Officer Bart Filius - Chief Operating Officer & Chief Financial Officer Walid Abi-Saab - Chief Medical Officer Michele Manto - Chief Commercial Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Jason Gerberry - Bank of America Charlie Mabbutt - Bernstein James Gordon - JPMorgan Matthew Harri ...

| --- | --- | |---------------------|-------| | | | | | | | 1Q 2022 results | | | May 6, 2022 webcast | | | | | This presentation contains "forward-looking statements." When used in this presentation, the words "anticipate," "could," "expect," "will," "plan," "potential," "estimate," "on track," "guidance," "ongoing," "outlook," and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding: the rate and timing of our cash ...

Galapagos NV (NASDAQ:GLPG) Q1 2022 Results Conference Call May 6, 2022 8:00 AM ET Company Participants Sofie Van Gijsel - Senior Director, Investor Relations Paul Stoffels - Chief Executive Officer Bart Filius - Chief Operating Officer & Chief Financial Officer Walid Abi-Saab - Chief Medical Officer Michele Manto - Chief Commercial Officer Conference Call Participants Matthew Harrison - Morgan Stanley Dane Leone - Raymond James Brian Abrahams - RBC Capital Markets Charlie Mabbutt - Bernstein Jason Gerberry ...

Financial Performance and Prospects - Galapagos has no historical product revenues, making it difficult to assess future prospects and financial results[21]. - The company has prioritized the development of certain product candidates due to limited resources and access to capital[26]. - The COVID-19 pandemic could materially and adversely affect the company's business and future growth prospects[34]. Product Development and Regulatory Challenges - The company is heavily dependent on the success of filgotinib, which is approved for rheumatoid arthritis and ulcerative colitis in the EU and Great Britain[23]. - Regulatory approval processes for product candidates are lengthy and unpredictable, impacting commercial viability[27]. - Future clinical trials may reveal significant adverse events that could inhibit regulatory approval or market acceptance[31]. Market and Competitive Landscape - Galapagos is currently building a marketing and sales organization to establish a European commercial infrastructure[22]. - Coverage and reimbursement decisions by third-party payers may adversely affect pricing and market acceptance of approved products[32]. - The company faces significant competition in drug discovery and development efforts, which could reduce commercial opportunities[32]. - The market price of the American Depositary Shares (ADSs) could be subject to wide fluctuations[35].

Compliance and Regulatory Filings - The registrant filed Form 20-F for annual reports, indicating compliance with SEC regulations[2] - The report includes information relevant to the registrant's securities and compliance with home country laws[3] Performance Information - The press release dated March 18, 2022, is attached as Exhibit 99.1, providing further details on the company's performance[5]